GlycoMimetics, Inc. (NASDAQ:GLYC) – Research analysts at Jefferies Group upped their FY2017 EPS estimates for shares of GlycoMimetics in a report issued on Wednesday. Jefferies Group analyst B. Amin now forecasts that the biotechnology company will post earnings of ($1.11) per share for the year, up from their previous estimate of ($1.28). Jefferies Group has a “Buy” rating and a $16.00 price target on the stock. Jefferies Group also issued estimates for GlycoMimetics’ Q4 2017 earnings at ($0.25) EPS, FY2018 earnings at $0.34 EPS, FY2019 earnings at ($1.17) EPS and FY2020 earnings at $0.37 EPS.

Several other research analysts have also weighed in on GLYC. Zacks Investment Research raised GlycoMimetics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Tuesday, July 18th. Roth Capital assumed coverage on GlycoMimetics in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 price target for the company. SunTrust Banks, Inc. restated a “buy” rating and set a $21.00 target price on shares of GlycoMimetics in a research note on Wednesday, October 4th. ValuEngine upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Stifel Nicolaus restated a “buy” rating and set a $17.00 target price (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $17.33.

WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/fy2017-eps-estimates-for-glycomimetics-inc-glyc-boosted-by-jefferies-group/1701548.html.

Shares of GlycoMimetics (GLYC) opened at $11.59 on Monday. GlycoMimetics has a 52-week low of $3.82 and a 52-week high of $16.94.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04.

In related news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $13.00, for a total value of $26,000.00. Following the completion of the sale, the senior vice president now directly owns 150,615 shares in the company, valued at $1,957,995. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 43.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of GLYC. Russell Investments Group Ltd. increased its holdings in GlycoMimetics by 172.4% in the second quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 19,859 shares during the period. TD Asset Management Inc. bought a new stake in GlycoMimetics during the second quarter valued at $362,000. Bank of New York Mellon Corp boosted its position in GlycoMimetics by 159.4% during the second quarter. Bank of New York Mellon Corp now owns 92,911 shares of the biotechnology company’s stock valued at $1,037,000 after acquiring an additional 57,091 shares during the last quarter. Jennison Associates LLC bought a new stake in GlycoMimetics during the second quarter valued at $17,786,000. Finally, Columbus Circle Investors bought a new stake in GlycoMimetics during the second quarter valued at $1,516,000. Institutional investors and hedge funds own 92.47% of the company’s stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.